Akero Therapeutics Inc (NAS:AKRO)
$ 20.27 0.13 (0.65%) Market Cap: 1.40 Bil Enterprise Value: 525.23 Mil PE Ratio: 0 PB Ratio: 1.66 GF Score: 41/100

Akero Therapeutics Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 12, 2021 / 04:00PM GMT
Release Date Price: $21.93 (+1.20%)
Ed Arce
H.C. Wainwright & Co. - Analyst

Hello, and welcome to the H.C. Wainwright 5th Annual NASH Investor Conference. My name is Ed Arce, and I'm one of the senior biotech analysts here at H.C. Wainwright, and I'm very pleased to have with us our next presenting company, Akero Therapeutics. And representing the company is Dr. Tim Rolph. He is the Co-Founder and Chief Scientific Officer of Akero. Tim, welcome.

Tim Rolph
Akero Therapeutics, Inc. - Co-Founder and Chief Scientific Officer

Delighted to be with you, Ed.

Ed Arce
H.C. Wainwright & Co. - Analyst

Great. Very glad to have you with us. Let's jump right in. Akero is a company well known to many investors that are following the space. But let's start off by going over the key takeaways from your prior main study, the BALANCED Phase 2a study in F2/F3 patients, including of course the profound liver fat reductions that you saw in that study. And I should mention that as well the full results of that study have now recently been published in the top-tier

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot